Premium
Loading mitomycin C inside long circulating hyaluronan targeted nano‐liposomes increases its antitumor activity in three mice tumor models
Author(s) -
Peer Dan,
Margalit Rimona
Publication year - 2003
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.11615
Subject(s) - in vivo , mitomycin c , liposome , medicine , cd44 , cancer research , hyaluronic acid , receptor , pharmacology , drug , in vitro , toxicity , metastasis , cancer , chemistry , biology , surgery , biochemistry , anatomy , microbiology and biotechnology
The frequent overexpression of the hyaluronan receptors CD44 and RHAMM in cancer cells opens the door for targeting by the naturally‐occurring high‐ M r hyaluronan. This is the first time effective in vivo tumor targeting is reported for mitomycin C (MMC) loaded inside nano‐sized hyaluronan‐liposomes (denoted tHA‐LIP). The severe adverse effects of free MMC made it a rational candidate for an effective targeted carrier. In vitro , loading MMC inside tHA‐LIP increased drug potency 100‐fold, in cells overexpressing, but not in cells underexpressing, hyaluronan receptors. Both types of liposomes were non‐toxic and reduced MMC‐related toxicity in healthy C57BL/6 mice. In 3 tumor models, BALB/c bearing C‐26 solid tumors; C57BL/6 bearing B16F10.9 or (separately) D122 lung metastasis, tHA‐LIP were long‐circulating, 7‐fold and 70‐fold longer than nt‐LIP and free MMC, respectively. tHA‐LIP‐mediated MMC accumulation in tumor‐bearing lungs was 20% of injected dose, compared to 0.6% and 4% with free drug and nt‐LIP, respectively. Tumor‐free lungs showed low accumulation, irrespective of drug formulation. Key indicators of therapeutic responses, tumor progression, metastatic burden and survival, were superior ( p < 0.001) in animals receiving MMC‐loaded tHA‐LIP, no treatment, MMC‐loaded nt‐LIP and free drug. In conclusion, tHA‐LIP perform as tumor‐targeted carriers, with promising prospects for treatment of tumors overexpressing hyaluronan receptors. © 2003 Wiley‐Liss, Inc.